title: Combination therapy with ARA-AMP and interferon of chronic active hepatitis B. Interim analysis of an ongoing study.
authors.affiliation: Hepatogastroenterology Unit, Hôtel-Dieu Hospital, Lyon, France.
authors.forename: C
authors.initials: C
authors.lastname: Trépo
authors.forename: P
authors.initials: P
authors.lastname: Rougier
authors.forename: T
authors.initials: T
authors.lastname: Bizollon
authors.forename: R
authors.initials: R
authors.lastname: Poupon
authors.forename: J P
authors.initials: JP
authors.lastname: Zarski
authors.forename: A
authors.initials: A
authors.lastname: Quinton
authors.forename: J P
authors.initials: JP
authors.lastname: Miguet
authors.forename: X
authors.initials: X
authors.lastname: Causse
authors.forename: P
authors.initials: P
authors.lastname: Chossegros
authors.forename: M
authors.initials: M
authors.lastname: Chevallier
mesh_terms: D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006509:Hepatitis B / Q000188:drug therapy* / Q000628:therapy; D006511:Hepatitis B Antigens / Q000032:analysis; D006515:Hepatitis B virus / Q000276:immunology; D006521:Hepatitis, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D011994:Recombinant Proteins; D001084:Vidarabine Phosphate / Q000627:therapeutic use*; D014779:Virus Replication
chemical_list: D006511:Hepatitis B Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D001084:Vidarabine Phosphate